Lung Cancer
Volume 69, Issue 1 , Pages 116-122 , July 2010

Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy

  • Jian Li

      Affiliations

    • Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, 438 North Jiefang Road, Zhenjiang 212001, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 511 84410008; fax: +86 511 84408611.
    • ,
  • Zhen-Nan Li

      Affiliations

    • Department of Clinical Medicine, Nanjing Medical University, Nanjing, China
    • ,
  • Li-Chao Yu

      Affiliations

    • Department of Thoracic Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China
    • ,
  • Qian-Lei Bao

      Affiliations

    • Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, 438 North Jiefang Road, Zhenjiang 212001, China
    • ,
  • Jian-Rong Wu

      Affiliations

    • Department of Pathology, Affiliated Hospital of Jiangsu University, Zhenjiang, China
    • ,
  • Shun-Bing Shi

      Affiliations

    • Department of Thoracic Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China
    • ,
  • Xiao-Qin Li

      Affiliations

    • Department of Medical Oncology, Affiliated Hospital of Jiangsu University, Zhenjiang, China

Received 16 April 2009 ,Revised 27 July 2009 ,Accepted 29 September 2009.

References 

  1. Bunn PA, Mault J, Kelly K. Adjuvant and neoadjuvant chemotherapy for non-small cell lung cancer. Chest. 2000;117(Suppl 1):119s–122s
  2. Voltolini L, Luzzi L, Ghiribelli , Paladini P, Bisceglie MD, Gotti G. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur J Cardio-thoracic Surg. 2001;20:1106–1112
  3. Betticher DC, Schmitz S-FH, Tőtsch M, Hansen E, Joss C, von Briel C, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small cell lung cancer: a multicenter phase II trial. J Clin Oncol. 2003;21:1752–1759
  4. Junker K, Langner K, Klinke F, Bosse U, Thomas M. Grading of tumor regression in non-small cell lung cancer: morphology and prognosis. Chest. 2001;120:1584–1591
  5. Young LC, Campling BG, Cole SPC, Deeley RG, Gerlach JH. Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer: correlation of protein levels with drug response and messenger RNA levels. Clin Cancer Res. 2001;7:1798–1804
  6. Young LC, Campling BG, Voskoglou-Nomikos T, Cole SPC, Deeley RG, Gerlach JH. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin Cancer Res. 1999;5:673–680
  7. Kawabata S, Oka M, Soda H, Shiozawa K, Nakatomi K, Tsurutani J, et al. Expression and functional analyses of breast cancer resistance protein in lung cancer. Clin Cancer Res. 2003;9:3052–3057
  8. Laurencot CM, Scheffer GL, Scheper RJ, Shoemaker RH. Increased LRP mRNA expression is associated with the MDR phenotype in intrinsically resistant human cancer cell lines. In J Cancer. 1997;72:1021–1026
  9. Berger W, Elbling L, Micksche M. Expression of the major vault protein LRP in human non-small-cell lung cancer cells: activation by short-team exposure to antineoplastic drugs. Int J Cancer. 2000;88:293–300
  10. Ota E, Abe Y, Oshika Y, Ozeki Y, Iwasaki M, Inoue H, et al. Expression of the multidrug resistance associated-protein (MRP) gene in non-small-cell lung cancer. Br J Cancer. 1995;72:550–554
  11. Nooter K, de la Reviere GB, Look MP, van Wingerden KE, Henzen-Logmans SC, Scheper RJ, et al. The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer. 1997;76:486–493
  12. Endo K, Meahara Y, Kusumoto T, Ichiyoshi Y, Kuwano M, Sugimachi K, et al. Expression of multidrug-resistance-associated protein (MRP) and chemosensitivity in human gastric cancer. Int J Cancer. 1996;68:372–377
  13. Cappi P, Volante M, Novello S, Rapa I, Danenberg KD, Danenberg PV, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17:1818–1825
  14. Lord RVN, Brabender J, Gandara D, Alberola V, Camps C, Domine M, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res. 2002;8:2286–2291
  15. Olaussen KA, Dunant A, Fouret P, Brambilla E, André F, Haddad V, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–991
  16. Mountain CF. Revision in the international system for staging lung cancer. Chest. 1997;111:1170–1717
  17. Scagliotti GV, Novello S, Selvaggi G. Multidrug-resistance in non-small-cell lung cancer. Ann Oncol. 1999;10:583–586
  18. Berger W, Selinek U, Hollaus P, Zidek T, Steiner E, Elbling L, et al. Multidrug-resistance markers P-glycoprotein, multidrug-resistance protein 1 and lung resistance protein in non-small cell lung cancer: prognostic implication. J Cancer Res Clin Oncol. 2005;131:355–363
  19. Volm M, Koomagi R, Mattern J, Efferth T. Protein expression profiles indicative for drug-resistance of non-small cell lung cancer. Br J Cancer. 2002;87:251–257
  20. Yoh K, Ishii G, Yokase T, Minegishi Y, Tsuta K, Goto K, et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res. 2004;10:1691–1697
  21. Filipits M, Haddad V, Schmid K, Huynh A, Dunant A, André F, et al. Multidrug resistance protein do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: international adjuvant lung cancer trial biologic program. Clin Cancer Res. 2007;13:3892–3898
  22. Bessho Y, Oguri T, Achiwa H, Muramatsu H, Maeda H, Niimi T, et al. Role of ABCG2 as a biomarker for predicting resistance to CPT-11/SN-38 in lung cancer. Cancer Sci. 2006;97:192–198
  23. Haimeur A, Conseil G, Deeley RG, Cole SP. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab. 2004;5:21–53
  24. Doyle LA, Ross DD. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene. 2003;22:7340–7358
  25. Imai Y, Tsukahara S, Asada S, Sugimoto Y. Phytoestrogens/flavonoids reverse breast cancer resistance protein/ABCG2-mediated multidrug resistance. Cancer Res. 2004;64:4346–4352
  26. Harada T, Ogura S, Yamazaki K, Kinoshita I, Itoh T, Isobe H, et al. Predictive value of expression of P53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancer. Cancer Sci. 2003;94:394–399
  27. Reed E. Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev. 1998;24:331–344
  28. Li Q, Yu JJ, Mu C, Yunmbaim MK, Slavsky D, Cross CL, et al. Association between the level of ERCC1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells. Anticancer Res. 2000;20:645–652
  29. Britten RA, Liu D, Tessier A, Hutchison MT, Murray D. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer. 2000;89:453–457

PII: S0169-5002(09)00497-8

doi: 10.1016/j.lungcan.2009.09.013

Lung Cancer
Volume 69, Issue 1 , Pages 116-122 , July 2010

Article Tools

* Image Usage & Resolution